MARAVAI LIFESCIENCES HOLDINGS, INC.
Maravai LifeSciences provides products and services that support the development of drugs, therapeutics, vaccines and diagnostics, as well as research on human disease. Its customers include biopharmaceutical companies, biotech firms, life science research organizations, academic institutions and diagnostics companies. Maravai operates two segments: TriLink, which supplies complex nucleic acids, enzymes and related materials and provides mRNA manufacturing services; and Cygnus, which provides biologics safety testing products and services. TriLink’s offerings include mRNA, oligonucleotides, CleanCap® capping technology, ModTail™ tail modification technology, synthesis inputs, nucleoside triphosphates and specialty enzymes. Cygnus sells impurity detection and viral clearance testing kits, ancillary reagents and custom analytical services. Maravai serves customers through direct and indirect sales, including distributors for customers outside the United States, and supports customers in approximately 60 countries. It occupies facilities in San Diego, California, Leland, North Carolina, Sterling, Virginia, and Jupiter, Florida.
No SEC Form 4 filings for $MRVI in the last 30 days.
See all $MRVI insider activity →Maravai LifeSciences (MRVI) raised its full-year revenue guidance to $212M-$216M and adjusted EBITDA forecast to $40M-$42M. Management expects Q4 GMP volumes to be higher than Q3 but cautioned about variability in order timing. The company plans to launch GMP-grade ModTail by year-end and added 70 discovery mRNA customers in Q3.
Maravai LifeSciences (MRVI) reports Q3 earnings Wednesday. Analysts expect a 6-cent loss per share on $43.4M revenue, down 16% sequentially. EPS estimates rose 38% in 60 days, with a $8.50 consensus target. Investors watch CleanCap revenue, GMP manufacturing, and cost discipline. MRVI trades at $7.45, near its 52-week range midpoint.
TriLink BioTechnologies, a Maravai LifeSciences company, secured a second CleanCap patent in China, expanding its IP protection for RNA technology. The new patent covers CleanCap cap analog compounds and related pharmaceutical compositions, complementing an earlier patent on synthesis methods. The patents strengthen TriLink's position in the RNA medicines market, with applications in mRNA vaccines and therapeutics.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MRVI (MARAVAI LIFESCIENCES HOLDINGS, INC.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent MRVI coverage spans earnings, financial news and technology.
Guidance raise suggests stronger demand and may support price appreciation.
No new data; investors will compare actual results to existing forecasts.
The new patent strengthens Maravai's competitive moat in the RNA therapeutics market.
Buy initiation may drive buying interest.
Analyst initiation with a Buy rating and a specific price target may attract buying interest and support the stock price.
AlphAI scores every news story that mentions MRVI with an AI model for sentiment and relevance, and aggregates insider trades from MARAVAI LIFESCIENCES HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Maravai LifeSciences (MRVI) raised its full-year revenue guidance to $212M-$216M and adjusted EBITDA forecast to $40M-$42M. Management expects Q4 GMP volumes to be higher than Q3 but cautioned about variability in order timing. The company plans to launch GMP-grade ModTail by year-end and added 70 discovery mRNA customers in Q3.
Maravai LifeSciences (MRVI) reports Q3 earnings Wednesday. Analysts expect a 6-cent loss per share on $43.4M revenue, down 16% sequentially. EPS estimates rose 38% in 60 days, with a $8.50 consensus target. Investors watch CleanCap revenue, GMP manufacturing, and cost discipline. MRVI trades at $7.45, near its 52-week range midpoint.
TriLink BioTechnologies, a Maravai LifeSciences company, secured a second CleanCap patent in China, expanding its IP protection for RNA technology. The new patent covers CleanCap cap analog compounds and related pharmaceutical compositions, complementing an earlier patent on synthesis methods. The patents strengthen TriLink's position in the RNA medicines market, with applications in mRNA vaccines and therapeutics.
Analysts made several calls on Monday. Morgan Stanley upgraded Wells Fargo to overweight, citing improved balance sheet growth. Bank of America initiated Vylor with a buy rating and $78 price target. Bernstein reiterated Nvidia as outperform, highlighting its datacenter opportunity. BMO initiated nVent Electric and Vertiv as outperform, citing growth in AI infrastructure and data centers. Jefferies initiated Samsara as buy, expecting strong revenue growth.
TD Cowen initiated coverage of Maravai Lifesciences with a Buy rating and a $9 price target. The company's TriLink division recently received a new China patent for its CleanCap technology. Maravai's stock has seen a 5.33% increase over 5 days and a 143.08% rise year-to-date.
Maravai LifeSciences (MRVI) reported a Q2 net loss of $21.6M but improved adjusted EBITDA to $8.7M. The company raised its full-year adjusted EBITDA guidance to $33M-$35M. Hedge funds are increasing their holdings, while short interest stands at 9.84% of float. MRVI's valuation hinges on sustained profit improvements and patent-protected technologies.
Maravai LifeSciences' (MRVI) subsidiary TriLink BioTechnologies received a China patent for its CleanCap mRNA compounds. The patent covers CleanCap cap analog compounds, RNA molecules, and pharmaceutical compositions. This is TriLink's second CleanCap patent in China, with the first covering synthesis methods. The patents protect both manufacturing processes and molecular structures. CleanCap technology is used in COVID-19 vaccines and various mRNA therapeutic development programs.
Maravai LifeSciences Holdings (MRVI) reported 1H 2026 revenue growth of 24% and adjusted EBITDA of $29M. The company attributed this to cost reductions, new leadership, and a diversified pipeline, positioning it for future profitable growth.
Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.
Maravai LifeSciences (MRVI) reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink at $34.7 million and Cygnus at $16.8 million. Adjusted EBITDA was $8.7 million, and GAAP net loss was $21.6 million. Full-year guidance: revenue $205-$215 million and adjusted EBITDA $33-$35 million.
